Form 4: Acumen Pharmaceuticals Director Jeffrey Ives Receives Significant Equity Compensation

Acumen Pharmaceuticals, Inc. Director Jeffrey L. Ives was granted 12,800 restricted stock units and options to purchase 19,500 shares of common stock on June 4, 2025, as part of his compensation package.

Summary

• Jeffrey L. Ives, a Director of Acumen Pharmaceuticals, Inc. (ABOS), reported the acquisition of equity securities.
• On June 4, 2025, Mr. Ives was granted 12,800 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in full on the earlier of the first anniversary of the grant date (June 4, 2026) or the 2026 annual stockholder meeting, contingent upon Mr. Ives' continuous service.
• Additionally, Mr. Ives was granted stock options to acquire 19,500 shares of Common Stock with an exercise price of $1.07 per share.
• These stock options will also vest in full on the earlier of the first anniversary of the grant date (June 4, 2026) or the 2026 annual stockholder meeting, subject to continuous service.
• The stock options have an expiration date of June 4, 2035.
• Following these transactions, Mr. Ives beneficially owns 12,800 shares of Common Stock directly and 19,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a standard practice that aligns the director's interests with the company's long-term performance and shareholder value, indicating continued commitment. It is a positive, but routine, disclosure.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with the long-term performance and shareholder value of Acumen Pharmaceuticals, Inc.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Risks

• The value of the granted equity awards (RSUs and stock options) is subject to the future performance and market price fluctuations of Acumen Pharmaceuticals' common stock.
• Vesting of the awards is contingent upon the reporting person's continuous service, meaning forfeiture could occur if service is terminated before vesting.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to the vesting schedule of the granted RSUs and stock options, which are set to vest in full on the earlier of June 4, 2026, or the 2026 annual stockholder meeting, subject to continuous service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize executive and board talent by aligning their interests with long-term company performance.

Related Party Transactions

• The transaction involves the grant of equity compensation to Jeffrey L. Ives, a Director of Acumen Pharmaceuticals, Inc., which is a standard related-party transaction for director remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for executive and director incentives within the company.

Next Steps

• The vesting of the 12,800 restricted stock units and 19,500 stock options will occur on the earlier of June 4, 2026, or the 2026 annual stockholder meeting, provided continuous service.

Key Dates

Recommendation

Keywords

Acumen Pharmaceuticals, ABOS, Jeffrey Ives, SEC Form 4, insider transaction, restricted stock units, RSU, stock options, equity compensation, director compensation, beneficial ownership